Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
1(33.3%)
N/A
1(33.3%)
Phase 1
1(33.3%)
3Total
Phase 2(1)
N/A(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04386863Completed

Taxonomy of Neurorehabilitation Treatments and Outcome Measures: a Multicentre Italian Study

Role: collaborator

NCT03167268Phase 2Unknown

Panitumumab Skin Toxicity Prevention Trial

Role: lead

NCT04816968Phase 1Unknown

Antibiotics Continuous Infusion at Home

Role: lead

NCT04673305Not ApplicableUnknown

Cognitive Status Assessment In Elderly Patients With Active Treatment For Haematological Malignancies

Role: lead

All 4 trials loaded